A Premier Forum for Oncoplastic Excellence

The Jornada Brasileira de Oncoplastia (JBO 2026) is scheduled to take place from July 30 to August 1, 2026, at the Centro de Convenções Frei Caneca in São Paulo. This prominent event gathers mastologists, plastic surgeons, and oncological surgeons to evaluate critical advancements in oncoplastic surgery and breast reconstruction. The scientific program addresses the fundamental modern surgical challenge: successfully uniting strict oncological rigor with aesthetic excellence. By integrating live surgical broadcasts, practical workshops, and targeted discussions on systemic therapies, the congress provides a comprehensive environment for deep clinical immersion.

Highlighting International Clinical Leadership

The advancement of reconstructive protocols relies upon the active exchange of global expertise, a core focus of the JBO 2026 program. Representing Italy, Prof. Pier Camillo Parodi is a featured international expert. Prof. Parodi currently serves as the Director of the Plastic Surgery Unit at the University Hospital Santa Maria della Misericordia in Udine. His extensive academic and clinical background includes active membership in the Italian Society of Plastic, Reconstructive and Aesthetic Surgery (SICPRE) and the American Society of Plastic Surgery. Additionally, his specialized roles as a university professor in Plastic and Reconstructive Surgery further demonstrate a career dedicated to elevating surgical education and addressing complex reconstructive methodologies.

Advanced Biomedical Concept: Advancing Biological Support

The clinical objectives driving JBO 2026 directly align with the overarching mission of Advanced Biomedical Concept. Founded in Rome in 2020 by an international consortium of breast surgeons, biomedical engineers, and healthcare specialists, the organization is committed to transforming biological innovation into tangible improvements for surgical outcomes worldwide. Advanced Biomedical Concept actively works to become the global reference for biological surgical support in breast reconstruction.

Guided by foundational principles such as Scientific Integrity and Surgeon Partnership, the company ensures that all medical devices, including the Exashape line, are developed to solve genuine clinical challenges backed by empirical evidence.

Furthermore, prioritizing comprehensive clinical resources and peer-reviewed data—such as the internally developed ExaShape Evidence Library—remains central to supporting the international surgical community and optimizing patient safety.

Important information This article is general education, not medical advice. Tap to read the full medical, regulatory & legal notice.

This article is provided by Advanced Biomedical Concept for general informational and educational purposes only. It does not constitute medical, surgical, diagnostic, or other professional healthcare advice, and it is not a substitute for consultation with a suitably qualified healthcare professional. Reading it creates no doctor–patient or other professional relationship. Nothing here should be used to diagnose, treat, cure, or prevent any disease or condition, or to make decisions about medical care. Always seek the advice of a physician or other qualified provider with any questions about a medical condition or treatment, and never disregard or delay professional advice because of something you have read here.

Any reference to Advanced Biomedical Concept products (including ExaShape and ExaFat) is provided for general information only. These are medical devices intended to be used by appropriately trained healthcare professionals strictly in accordance with their applicable, current Instructions for Use (IFU). Regulatory status (including CE marking and classification under the EU Medical Device Regulation), market availability, and approved indications differ between countries and may change over time; a device referred to here may not be available or approved in your country. This content is not intended as, and must not be relied upon as, a statement or claim of safety, clinical performance, or efficacy beyond what is set out in the applicable IFU and current regulatory approvals. Product-specific information is directed at healthcare professionals and is not intended to promote, advertise, or offer any medical device to the general public where such promotion is restricted or prohibited by law.

Statements reflect information believed to be accurate at the date of publication and may be updated or corrected without notice. Any statements regarding the future are expectations or general views, not guarantees. Clinical outcomes depend on many individual factors, results vary from person to person, and no particular result is promised or implied. Where third-party studies, sources, or external links are referenced, they are provided for convenience and information only and do not imply endorsement, and Advanced Biomedical Concept is not responsible for their content.

To the fullest extent permitted by applicable law, Advanced Biomedical Concept and its officers, employees, contributors, and representatives (each acting in that capacity and on behalf of Advanced Biomedical Concept) accept no liability for any loss, injury, or damage of any kind arising directly or indirectly from use of, or reliance on, this content. Nothing in this notice excludes or limits any liability that cannot lawfully be excluded or limited.

Questions about this material can be directed to us via our contact page.

Last reviewed: July 28, 2026.